Saltar al contenido

Dexcom Inc (DXCM) stock: revenue, earnings & dividend

Dexcom Inc (DXCM, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener DXCM · Nasdaq Medizintechnik & Messgeräte US-CA

Key figures

Fiscal year
2025
Revenue
4.66 bn $
Revenue growth
15.6 %
Revenue growth 5y (p.a.)
19.3 %
Net income
836 m $
Net margin
17.9 %
Operating margin
19.6 %
Earnings per share (diluted)
2.09 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
6.34 bn $
Equity
2.75 bn $
Equity ratio
43.3 %
Return on equity
30.5 %
Cash
918 m $
Operating cash flow
1.44 bn $
Free cash flow
1.08 bn $
Shares outstanding
372,950,922

History

Revenue by fiscal year

2016 573 m $
2017 719 m $
2018 1.03 bn $
2019 1.48 bn $
2020 1.93 bn $
2021 2.45 bn $
2022 2.91 bn $
2023 3.62 bn $
2024 4.03 bn $
2025 4.66 bn $

Net income by fiscal year

2016 -65.6 m $
2017 -50.2 m $
2018 -127.1 m $
2019 101 m $
2020 550 m $
2021 217 m $
2022 341 m $
2023 542 m $
2024 576 m $
2025 836 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20254.66 bn $836 m $2.09 $–1.44 bn $
20244.03 bn $576 m $1.42 $–990 m $
20233.62 bn $542 m $1.30 $–749 m $
20222.91 bn $341 m $0.82 $–670 m $
20212.45 bn $217 m $0.53 $–443 m $
20201.93 bn $550 m $1.33 $–476 m $
20191.48 bn $101 m $1.10 $–315 m $
20181.03 bn $-127.1 m $-1.44 $–123 m $
2017719 m $-50.2 m $-0.58 $–92 m $
2016573 m $-65.6 m $––56.2 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)